IP Library Granted Patent US 10,106,771
Granted Patent B2
US 10,106,771 · App. 15/684,647 · Granted Oct 23, 2018

Induction of hemogenic endothelium from pluripotent stem cells by forced expression of transcription factors

Inventors: Igor Slukvin (Verona, WI); Irina Elcheva (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0606C12N5/0608C12N5/0647C12N15/00C12N15/66C12N15/11C12N2501/60C12N2501/998C12N2506/02C12N2506/45C12N2510/00C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,771
App. No.
15/684,647
Granted
Oct 23, 2018
Kind
B2
Abstract

Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.

Claims (10)

1. A recombinant human pluripotent stem cell comprising:

(i) one or more exogenous expression cassettes comprising nucleic acids encoding

(a) an ETV2 or ERG protein, and a GATA1 protein; or

(ii) exogenous polypeptides comprising the amino acid sequences of (a).

2. The recombinant human pluripotent stem cell of claim 1 , wherein the exogenous polypeptides comprise a protein transduction domain.

3. The recombinant human pluripotent stem cell of claim 1 , wherein the recombinant human pluripotent stem cell does not contain an integrated expression cassette.

4. The recombinant human pluripotent stem cell of claim 3 , wherein the one or more exogenous nucleic acids are episomal plasmid expression vectors.

5. The recombinant human pluripotent stem cell of claim 3 , wherein the one or more exogenous nucleic acids are modified mRNAs (mmRNAs).

6. A cell culture composition for generating human hemogenic endothelial cells with pan-myeloid potential defined as the capacity of producing granulocyte, monocyte/macrophages, erythroid cells and megakaryocytes, comprising the recombinant human pluripotent stem cell of claim 1 and a cell culture medium suitable for expansion of hematopoietic cells.

7. The cell culture composition of claim 6 , wherein the cell culture medium comprises FGF2, SCF, and thrombopoietin.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 5, 2017
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043750/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2017
From: SLUKVIN, IGOR; ELCHEVA, IRINA
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 043463/0616 →
Continuity (4)
Division 15183191 · Jun 15, 2016
Division 14058959 · Oct 21, 2013
Provisional Application 61716875 · Oct 22, 2012
Related Publication 20180010124A1 · Jan 11, 2018